Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-024-04733-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Shuo Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics & Soft Tissue, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital…. Hauptthemen laut MEDLINE: Osteosarcoma, Protein Phosphatase 2, NF-kappa B, Cell Proliferation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Hunan Science and medicine joint fund project.
Abstract (Originalsprache)
BACKGROUND: Polygala tenuifolia and its active components have been revealed to possess anti-tumor activities. However, the role of Tenuigenin (TEN), a bioactive ingredient from Polygala tenuifolia, in tumors such as osteosarcoma (OS) remains unclear. The present research intended to explore the efficacy and underlying mechanism of TEN on OS. METHODS: OS cells were administrated with different concentrations of TEN. Cell viability, proliferation, invasion, and migration were assessed with CCK-8 assay, colony formation assay, transwell assay, and wound healing assay, respectively. Protein and mRNA levels were determined with western blot and qRT-PCR, while protein phosphatase 2A (PP2A) activity was tested with PP2A phosphatase assay kit. The interaction between PP2A and cancerous inhibitor of protein phosphatase 2A (CIP2A) or nuclear factor kappaB (NF-κB) signaling was detected using co-immunoprecipitation. p-p65 expression in the nucleus was determined with immunofluorescence. The efficacy of TEN in vivo was also explored in a xenograft tumor model. Immunohistochemistry was performed to detect CIP2A and Ki67 in mice. RESULTS: TEN treatment or CIP2A depletion repressed cell viability, proliferation, invasion, and migration in OS cells. Additionally, TEN reduced CIP2A, increased PP2A activity, and inactivated NF-κB signaling. PP2A directly interacted with CIP2A or NF-κB signaling, and PP2A inhibition reversed CIP2A knockdown-induced repression of NF-κB signaling. CIP2A overexpression overturned the efficacy of TEN, which was reversed by NF-κB inhibition. TEN decreased CIP2A, elevated PP2A activity, inactivated NF-κB signaling, and inhibited tumor growth in vivo, which was antagonized by CIP2A overexpression. CONCLUSION: TEN suppressed OS growth via CIP2A/PP2A/NF-κB axis, indicating that it would be a novel drug for treating OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics & Soft Tissue, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, No. 283, Tongzipo Road, Yuelu District, Changsha, 410013, Hunan Prov…
- Department of Comprehensive Bone and Joint Rehabilitation, Hunan Provincial Rehabilitation Hospital, Changsha, 410007, Hunan Province, People's Republic of China.
Förderung
- Hunan Science and medicine joint fund project
Zitieren
APA
Yang, S., Liu, S., & Dai, Z. (2025). Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04733-w
Vancouver
Yang S, Liu S, Dai Z. Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-024-04733-w
BibTeX
@article{Yang2025,
author = {Yang, Shuo and Liu, Shasha and Dai, Zixun},
title = {Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-024-04733-w}
}
EUVIMED